Investors in Novo Nordisk A/S Should Contact The Gross Law Firm Before March 25, 2025 to Discuss Your Rights – NVO

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Novo Nordisk A/S regarding a class action lawsuit following disappointing results from the "REDEFINE 1" trial of CagriSema, which led to a significant drop in the company's stock price [1][3]. Group 1: Trial Results and Impact - The "REDEFINE 1" trial, which investigated the efficacy and safety of subcutaneous CagriSema, reported a weight loss of 22.7% after 68 weeks, falling short of Novo's target of at least 25% [3]. - Only 57.3% of patients in the trial were on the highest dosage, as participants were allowed to modify their own dosage during the study [3]. - Following the announcement of these results, Novo's stock price decreased by $18.44, closing at$85.00 per share [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as November 2, 2022, to December 19, 2024, and shareholders are encouraged to register for participation [3][4]. - The deadline for shareholders to seek lead plaintiff status is March 25, 2025, and there is no cost or obligation to participate in the case [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [5].